Aptorum Group Ltd (APM) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical...